PropertyValue
?:abstract
  • Patients with cancer should benefit from COVID-19 vaccination. Some of the most advanced vaccine candidates are mRNAs encapsulated into lipid carriers, and small liposomes are expected to accumulate in tumour tissues through the enhanced and permeation retention effect. However, to what extent solid tumours could take up a significant part of the vaccine dose as well remains unknown. This calls for a careful evaluation of the efficacy of these promising mRNA COVID-19 vaccines administered as lipid carriers for patients with solid tumours, including a possible re-appraisal of the dosing for optimal protection of this specific and frail population.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1038/s41416-020-01219-3
?:journal
  • Br_J_Cancer
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/c164f0e53f811d986c98354506c904c4c81f9e51.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7720437.xml.json
?:pmcid
?:pmid
?:pmid
  • 33288844.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • COVID-19 vaccine race: watch your step for cancer patients
?:type
?:year
  • 2020-12-07

Metadata

Anon_0  
expand all